Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | May 21, 2024
Discovery & Translation
Big data for a rare disease: FNIH takes on ALS
In partnership with FDA, industry and disease foundations, FNIH is creating a one-stop shop for data on the rare disease to spur diagnostics and therapeutics development
BioCentury | Feb 24, 2024
Discovery & Translation
Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 30, 2022
Data Byte
Assessing an expanse of ALS targets
Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Feb 25, 2022
Discovery & Translation
UNC13A mis-splicing in ALS/FTD; plus Soteria, Boston Pharma and more
BioCentury’s roundup of translational news
BioCentury | Feb 5, 2022
Discovery & Translation
Wave’s oligos enhance tissue exposure; plus Rosenberg, Disney and more
BioCentury’s roundup of translational news
BioCentury | Jun 24, 2021
Deals
BMS likes what it sees from Prothena’s anti-tau targeting approach, opts in for clinical mAb
By exercising an option it acquired via its takeout of Celgene, BMS is paying $80 million for U.S. rights to an anti-tau asset for Alzheimer’s disease that Prothena believes could be best in
BioCentury | May 20, 2021
Deals
Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies
The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
BioCentury | Dec 11, 2020
Emerging Company Profile
Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology
Emerging Company Profile: dissecting normal and pathogenic biomolecular condensate biology to enable drug development
Items per page:
1 - 10 of 65